Consensus Verastem, Inc.

Stocks

VSTM

US92337C2035

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 05/09/2026 +04			5-day change	1st Jan Change
8.200 ^USD	+2.76%		+13.57%	+6.22%

08-11	Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating	MT
08-07	Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million	CI

Evolution of the Average Target: Verastem, Inc.

Evolution of the Target Price: Verastem, Inc.

Changes in Analyst Recommendations: Verastem, Inc.

037ff511d6de4aa5abf87b302f76.-5SFG8DOkbC1bUAFuzH5NVv_im1nOe_dPXg1Queo48w.k6fafree9d3sAgU33wLNAAqzyz9fTrnpdxZxI5__gZ_K5vZu8v6m9ucENw~5f47decfc4644aa745da2538a0f4478e

Analysts' recommendations: Verastem, Inc.

08-11	Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating	MT
07-07	RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating	MT
06-24	Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says	MT
05-14	Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Keeps Verastem Price Target to $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating	MT
01-08	RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk	MT
11-05	RBC Capital Adjusts Verastem Price Target to $14 From $13, Maintains Outperform Rating	MT
19/10/25	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma	CI
26/08/25	B. Riley Raises Price Target on Verastem to $16 From $13, Keeps Buy Rating	MT
15/08/25	Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
08/08/25	RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk	MT
25/06/25	RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk	MT
09/05/25	B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating	MT
09/05/25	Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating	MT
09/05/25	RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk	MT
28/04/25	B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating	MT
10/04/25	Jefferies Initiates Verastem at Buy With $15 Price Target	MT
08/04/25	Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating	MT
21/03/25	RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
31/01/25	B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating	MT
07/01/25	RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk	MT
31/12/24	BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating	MT
18/12/24	Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating	MT
30/09/24	Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERASTEM, INC.					+82.93%
	WUXI APPTEC CO., LTD.					+21.09%
	ARGENX SE					+11.95%
	INSMED INCORPORATED					+58.51%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.61%
	BIONTECH SE					+15.94%
	GENMAB A/S					+12.11%
	PHARMAESSENTIA CORPORATION					+6.66%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.36%
	EXELIXIS, INC.					-9.02%
	Average					+24.31%
	Weighted average by Cap.					+19.11%